CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene
Portfolio Pulse from
CG Oncology, Inc. announced positive phase 3 results for Cretostimogene in treating BCG-unresponsive NMIBC, with plans to expand its use and potentially file a BLA. The therapy shows increased efficacy when combined with KEYTRUDA.
December 13, 2024 | 7:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CG Oncology's positive phase 3 results for Cretostimogene could lead to a BLA submission, potentially boosting the company's market position and stock price.
The positive phase 3 results for Cretostimogene are a significant milestone for CG Oncology, potentially leading to a BLA submission. This development could enhance the company's market position and drive stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100